← Leaderboards
George Somlo
University Of Southern California
$546,055
Attributed
$546,055
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $92.8K · FY2005–09$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$546,055 · 8
By mechanism
M01$546,055 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Heinz Josef Lenz$20,123,312
- John A Zaia$8,207,353
- Derek Raghavan$1,863,220
- Christy Russell$719,837
- David K Ann$16,827,823
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCyclophosphamideHuman SubjectNeoplasm /Cancer ChemotherapyCombination Cancer TherapyHuman Therapy EvaluationCombination ChemotherapyDoxorubicinNeoplasm /Cancer SurgeryNeoplasm /Cancer ImmunotherapyMelphalanPaclitaxelBreast NeoplasmsColony Stimulating FactorBone Marrow TransplantationCis Platinum CompoundHomologous TransplantationFutureGrantChemotherapyComputer Retrieval Of Information On Scientific Projects DatabaseErbb2 GeneFundingDocetaxel
Grant awards (13)
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN$92,760
M01 · FY2009 · RR · contact PI
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN$57,683
M01 · FY2008 · RR · contact PI
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN$59,115
M01 · FY2007 · RR · contact PI
DOSE-INTENSE CHEMOTHERAPY AND STEM CELL RESCUE IN THE TREATMENT OF INFLAMMATORY$45,725
M01 · FY2006 · RR · contact PI
RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADRIAMYCIN AND CYTOXAN$4,354
M01 · FY2006 · RR · contact PI
PHASE II RANDOMIZED TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB AND THALIDOMIDE$3,099
M01 · FY2005 · RR
Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory$77,024
M01 · FY2004 · RR
Phase II Randomized Trial of Bevacizumab vs. Bevacizumab$14,978
M01 · FY2004 · RR
DOSE INTENSE CHEMOTHERAPY &STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER$0
M01 · FY2002 · RR
DOSE INTENSE CHEMOTHERAPY &STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER$155,764
M01 · FY2001 · RR
DOSE INTENSE CHEMOTHERAPY &STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER$0
M01 · FY2001 · RR
DOSE INTENSE CHEMOTHERAPY &STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER$35,553
M01 · FY2000 · RR
DOSE INTENSE CHEMOTHERAPY &STEM CELL RESCUE IN INFLAMMATORY BREAST CANCER$0
M01 · FY2000 · RR